WHO backs antibody treatment Regeneron for high-risk COVID patients | Inquirer News

WHO backs antibody treatment Regeneron for high-risk COVID patients

/ 08:00 AM September 24, 2021

WHO backs antibody treatment Regeneron for high-risk COVID patients

(FILES) In this file photo taken on February 24, 2020, shows the logo of the World Health Organization (WHO) at its headquarters in Geneva. (Photo by Fabrice COFFRINI / AFP)

Paris, France  — The World Health Organization (WHO) on Friday recommended the synthetic antibody treatment Regeneron for COVID-19, but only in patients with specific health profiles.

Persons with non-severe COVID-19 who are nonetheless at high risk of hospitalization can take the antibody combo, as should critically ill patients unable to mount an adequate immune response, according to a WHO finding published in BMJ.


Regeneron is only the third treatment for COVID to be recommended by the global health authority, which added it to its “living WHO guideline” on drugs for COVID-19.


In July, WHO gave the nod to a class of drugs that act to suppress a dangerous overreaction of the immune system to the SARS-CoV-2 virus that causes the coronavirus disease.

These medicines work well in tandem with corticosteroids, which were first recommended by WHO for use in COVID patients in September 2020.

The Regeneron cocktail of synthetic antibodies — casirivimab and imdevimab — has been found to reduce the risk of hospitalization for unvaccinated, elderly, or immunosuppressed patients with the coronavirus, according to three clinical trials that have yet to be peer-reviewed, according to the BMJ.

For the second category of patients covered by the new WHO recommendation, another trial has reported a reduced number of deaths, and cases requiring mechanical ventilation, in patients taking the drugs.

“For all other COVID-19 patients, any benefits of this antibody treatment are unlikely to be meaningful,” the WHO concluded.

Designed by biotech firm Regeneron and marketed by pharmaceutical giant Roche under the name Ronapreve, the treatment was given to former US President Donald Trump during his brush with coronavirus.


When used together, the monoclonal antibodies casirivimab and imdevimab bind to the SARS-CoV-2 spike protein, neutralizing the virus’s ability to infect cells.

The WHO “welcomes the addition of another therapeutic to the world’s arsenal against COVID-19”, but expressed concern about the impact of high prices on health inequality.

“Given the high cost and low availability of the combination therapy, [global health agency] UNITAID is negotiating with Roche Pharmaceutical … for lower prices and equitable distribution across all regions, especially in low- and middle-income countries,” the WHO said in a separate statement.

“WHO is also in discussions with the company for a donation and distribution of the drug through UNICEF.”

The UN health authority also called on other manufacturers to submit “bio-similar” versions of the drug for approval.

In July, Japan had become the first country to fully approve Regeneron’s antibody treatment for patients with mild to moderate Covid-19.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

The antibody combination has been authorized for emergency or temporary pandemic use in a number of countries and regions, including the European Union, United States, India, Switzerland, and Canada.

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.

TAGS: antibody, COVID-19, Health, Regeneron, roche, Ronapreve, WHO

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.